[{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":1,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Immedica Pharma AB","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Immedica Pharma AB"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Megapharm"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Stand Up To Cancer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Stand Up To Cancer","highestDevelopmentStatusID":"1","companyTruncated":"Jazz Pharmaceuticals \/ Stand Up To Cancer"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Eczac\u0131ba\u015f\u0131 Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"DNA adduct formation","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"CDK12","graph1":"Oncology","graph2":"Preclinical","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Lurbinectedin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) is being investigated as a maintenance treatment for adults with extensive-stage small cell lung cancer.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 15, 2024

                          Lead Product(s) : Lurbinectedin,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 12, 2023

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : PharmaMar

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin) inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 08, 2023

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in dis...

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 26, 2022

                          Lead Product(s) : Lurbinectedin,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : PharmaMar

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Cosela (trilaciclib), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.

                          Brand Name : Cosela

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 26, 2022

                          Lead Product(s) : Trilaciclib,Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 17, 2022

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : PharmaMar

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect the activity of DNA binding proteins, and DNA repair pathways, resulting in disruption of cell cycle and eventual cell de...

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 12, 2022

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : CDK12 inhibitor demonstrates strong anti-tumor activity as single agent and in combination with a DNA damaging agent and a PARP inhibitor in models of breast, lung, and ovarian cancer.

                          Brand Name : SY-5609

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2022

                          Lead Product(s) : SY-5609,Olaparib,Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Zepzelca (lurbinectedin), is an alkylating drug that binds guanine residues within DNA, triggers a cascade of events that can affect activity of DNA binding proteins, including some transcription factors resulting in disruption of cell cycle and eventual...

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 24, 2022

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Sma...

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 22, 2021

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Eczacıbaşı Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank